Bandingkan Harga & Kinerja Mitrabahtera Segara Sejati Tbk. (MBSS) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Mitrabahtera Segara Sejati Tbk. dan Organon Pharma Indonesia Tbk.: Mitrabahtera Segara Sejati Tbk. diperdagangkan di Rp2.890 (kapitalisasi pasar 5,04 T, volume 24 jam 2,48 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Mitrabahtera Segara Sejati Tbk. jauh lebih besar — sekitar 48,3× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| MBSS | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 5,04 T | 104,4 M |
Volume | 2,48 jt | — |
Lot | 24,83 rb | — |
Perputaran | 7,17 M | — |
Harga Rata-rata | 2.888,23 | — |
Nilai Transaksi | 7,17 M | — |
Harga Ekuilibrium Indikatif | 2.890 | — |
Volume Ekuilibrium Indikatif | 783 | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Mitrabahtera Segara Sejati Tbk.
PT Mitrabahtera Segara Sejati Tbk (the company) was established on 24 Mar 1994 based on Notaries Deed No. 107 and the deed of establishment was approved by the the Ministry of Justice dated Nov 6, 1996. The Company’s articles of association has been amended several times, most recently by notarial deed No. 5 of Fathiah Helmi, S.H., dated Dec 13, 2010, concerning among others, the change in the Company’s name, and public offering.
Selengkapnya di halaman MBSS →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
